Archive:
Prof. Dr. med. Dipl.-Social Joachim Szecsenyi in the MVF cover interview
01.02.2010
Cost-benefit assessment of platelet aggregation inhibitors:
01.02.2010
He has been a general practitioner since 1983 and knows the concerns and needs of his profession inside out. To make a difference, Ulrich Weigeldt became a medical official: first in the Medical Association, then in the Bremen Medical Association and the German Medical Association, and finally, he even served on the board of the KBV (German Medical Association) for primary care. As such, he brought […]
01.02.2010
Comment from Dr. Axel Munte and Univ.-Prof. Dr. med. Matthias Schrappe
01.02.2010
The Challenge of Dementia – Developing Care Structures for the Future According to Benjamin Gompertz's (1779-1865) law, a person's age increases linearly. However, the probability of developing a chronic illness, becoming dependent on care, or developing dementia increases exponentially over the course of life [Gompertz, 1825]. In our aging society, dealing with [...]
01.02.2010
With the entry into force of Section 73b SGB V as amended by GKV-Org WG, all statutory health insurance companies were obliged to offer their insured persons special family doctor care (family doctor-centered care) by June 30, 2009. The consequence of these contracts is an adjustment of the total remuneration. The effects of an adjustment of the total remuneration on the individual doctor and practice were and are the subject of heated discussions at various levels.
01.02.2010
If we exploit the current potential for savings in healthcare, also in view of the experiences of other countries that spend significantly less money on longer life expectancy, we can delay the inevitable point of later rationing for a long time. However, it is important to send clear signals against the wrong incentive systems, which are essentially fed by sales-intensive, financially lucrative areas. Even though this is an unvalidated estimate, we can go another 10 years or so without rationing.
01.02.2010
The idea behind the introduction of individual contractual elements such as drug discount agreements into the statutory health insurance system is to initiate quality and performance competition between the health insurance companies. The necessary basic prerequisite for this competition to function is performance differentiation and the perception of these differences by the consumer. Only then can the insured represent a demand-side corrective for the competitive result through their health insurance choices. The answers to a current population survey by the Allensbach Institute for Demoscopy show that these requirements are not met and that expectations with regard to the quality of the services offered and the quality of care are hardly justified. The prospects of eliminating existing information deficits on the consumer side through targeted communication strategies must be assessed differently for the different supply areas.
01.02.2010
Unter welchen Voraussetzungen telemedizinische Angebote medizinisch, wirtschaftlich und technisch sinnvoll sind und wie sie in den Leistungskatalog der Kassen aufgenommen werden können, war Thema der 14. TELEMED-Fachtagung.
18.12.2009
Prof. Dr. rer. nat. Gerd Glaeske (Center for Social Policy at the University of Bremen) in the MVF cover interview